SIC
CSTL icon

SJS Investment Consulting’s Castle Biosciences CSTL Stock Holding History

SJS Investment Consulting’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$358 Sell
15
-4
-21% -$89 ﹤0.01% 2356
2026
Q1 		$467 Buy
+19
New +$622 ﹤0.01% 1770

Other funds holding CSTL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $123B AUM 45.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SPPAM
Summit Partners Public Asset Management Boston, Massachusetts $5.69B AUM 259.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SJS Investment Consulting's CSTL Position: Q2 2026 in Review

SJS Investment Consulting reduced its Castle Biosciences (CSTL) stake by 21% in Q2 2026, selling an estimated $89 and leaving 15 shares worth $358. The position accounts for ﹤0.01% of the portfolio, ranked #2356.

SJS Investment Consulting first reported a position in CSTL in Q1 2026 and has held it in 2 quarters since. The position peaked at $467 in Q1 2026. 177 funds tracked by Wall St. Rank hold CSTL as of Q2 2026.

  • SJS Investment Consulting held 15 shares of Castle Biosciences worth $358 as of Q2 2026.
  • SJS Investment Consulting sold 4 Castle Biosciences shares in Q2 2026, an estimated $89.
  • Castle Biosciences made up ﹤0.01% of SJS Investment Consulting's portfolio in Q2 2026, its #2356 holding.
  • SJS Investment Consulting first reported a position in Castle Biosciences in Q1 2026 and has held it in 2 quarters since.
  • SJS Investment Consulting's Castle Biosciences position peaked at $467 in Q1 2026.
  • 177 funds tracked by Wall St. Rank held Castle Biosciences as of Q2 2026.

Based on SJS Investment Consulting's 13F filing for Q2 2026, filed 22 Jul 2026.